Filter posts

Greenwood comment on PABNAB

BIO and BIO’s Board-level Workforce Development, Diversity and Inclusion (WDDI) Committee were disappointed that the …

Lupus Patients Find Hope In the Face of Hardship

One and a half million and counting. That’s how many people suffer from lupus in …

On the President’s Drug Cost Plan, Three Important Concerns

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its …

Diversity in Biopharma Leadership Makes Dollars and Sense

A series of recent studies examining diversity and financial performance have fueled a growing insistence …

The Latest Good News on Prescription Drug Costs

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These …

Orrin Hatch Is an Historic Figure in Biotechnology

As BIO CEO, everywhere I go – including Tokyo and Hong Kong last month – …

Flashback Friday: BIO '97 Rodeo & Ranch Party

This post is part of BIO’s yearlong, bi-weekly series called Flashback Friday, highlighting newsletter stories …

Flashback Friday: How FDA is Changing its Regulation of Biotechnology

This post is part of BIO’s yearlong, bi-weekly series called Flashback Friday, highlighting newsletter stories …

Flashback Friday: Getting to the Grassroots of the Matter

This post is part of BIO’s yearlong, bi-weekly series called Flashback Friday, highlighting newsletter stories …

BIO Unveils Refreshed Advocate Toolkit

This past March, BIO launched DrugCostFacts.org, an interactive web tool designed to help policymakers, members of …